Schrodinger Financial Statements
NASDAQ: SDGRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Schrodinger revenue and earnings
In fiscal 2025, Schrodinger generated $255.9 million in revenue, up 23.3% from fiscal 2024. Schrodinger reported a net loss of $103.3 million, compared with a loss of $187.1 million a year earlier. Gross margin was 55.7% (down from 63.6%) and operating margin -65.2%.
Diluted earnings per share came in at -$1.41. Over the last 5 fiscal years, SDGR's revenue has grown at a 18.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Schrodinger income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 255.87M | 207.54M | 216.67M | 180.96M | 137.93M | 108.09M | 85.54M |
| Revenue growth (YoY) | +23.29% | -4.21% | +19.73% | +31.19% | +27.60% | +26.36% | — |
| Cost of Revenue | 113.25M | 75.46M | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M |
| Gross Profit | 142.61M | 132.08M | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M |
| Operating Expenses | 309.51M | 341.38M | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M |
| Research & Development | 173.14M | 201.78M | 181.77M | 126.37M | 90.90M | 64.69M | 39.40M |
| Selling, General & Admin | 136.37M | 139.59M | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M |
| Operating Income | -166.90M | -209.30M | -177.45M | -146.82M | -111.44M | -60.92M | -38.72M |
| Other Income (Expense) | 64.57M | 23.59M | 220.37M | -2.31M | 10.63M | 34.62M | 12.74M |
| Pretax Income | -102.33M | -185.71M | 42.92M | -149.12M | -100.81M | -26.29M | -25.97M |
| Income Tax | 939.00K | 1.41M | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K |
| Net Income | -103.27M | -187.12M | 40.72M | -149.19M | -100.39M | -24.46M | -24.57M |
| Net Income growth (YoY) | — | -559.54% | — | — | — | — | — |
| EPS (Basic) | -1.41 | -2.57 | 0.57 | -2.10 | -1.42 | -0.41 | -4.09 |
| EPS (Diluted) | -1.41 | -2.57 | 0.54 | -2.10 | -1.42 | -0.41 | -4.09 |
| Shares Outstanding (Basic) | 73.44M | 72.67M | 71.78M | 71.17M | 70.59M | 60.02M | 6.00M |
| Shares Outstanding (Diluted) | 73.44M | 72.67M | 74.99M | 71.17M | 70.59M | 60.02M | 6.00M |
| EBITDA | -160.87M | -203.14M | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M |
| Gross Margin | 55.74% | 63.64% | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% |
| Operating Margin | -65.23% | -100.85% | -81.90% | -81.13% | -80.80% | -56.35% | -45.26% |
| Net Margin | -40.36% | -90.16% | 18.79% | -82.44% | -72.78% | -22.63% | -28.72% |
This table shows 7 annual periods of Schrodinger's income statement, from FY 2025 back to FY 2019, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow SDGR's reporting calendar. What is a income statement?